Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 60

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 60
---
 the
acknowledgments, understandings, agreements, representations and warranties set forth in of this Agreement are no longer accurate.

5.2 . The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the
Nasdaq Capital Market and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company’s reporting, filing and other obligations under the rules and regulations of Nasdaq.

5.3 . The Company shall, by 9:00 a.m., New York City time, on the first Business Day immediately following
the date of this Agreement, file with the SEC a Current Report on Form 8-K or issue a press release (the “Disclosure Document”) disclosing (i) all material terms of the transactions
contemplated hereby and by the other Transaction Agreements, and (ii) all material non-public information (if any) concerning the Company disclosed by the Company or its representatives to the Investors.
Following the filing of the Disclosure Document, no Investor shall be in possession of any material non-public information concerning the Company disclosed to the Investors by the Company or its
representatives. The Company understands and confirms that the Investors will rely on the foregoing representation in effecting securities transactions. Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly
disclose the name of any Investor or any of its affiliates or advisers, or include the name of any Investor or any of its affiliates or advisers in any press release, public announcement or filing with the SEC or any regulatory agency, without the
prior written consent of the Investor, except (i) as required by the federal securities laws in connection with (A) any registration statement contemplated by this Agreement and (B) the filing of final Transaction Agreements with the
SEC or pursuant to other routine proceedings of regulatory authorities, or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Capital Market.

5.4 . The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the
Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that
would require the registration under the Securities Act of the sale of the Securities to the Investors, or that will be integrated with the